Inicio ›

Publications

Filtros: Autor es Salazar, J  [Restablecer todos los filtros]
2011
Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British journal of cancer. 2011;105(1):53-7. Abstract
Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. International journal of radiation oncology, biology, physics. 2011;81(5):1319-27. Abstract
2010
Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer science. 2010;101(9):2048-53. Abstract
Páez D, Paré L, Altés A, Sancho-Poch FJ, Petriz L, Garriga J, et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. Journal of cancer research and clinical oncology. 2010;136(11):1681-9. Abstract
Paré L, Paez D, Salazar J, del Rio E, Tizzano E, Marcuello E, et al. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. British journal of clinical pharmacology. 2010;70(2):268-72. Abstract
2008
Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British journal of cancer. 2008;99(7):1050-5. Abstract
Paré L, Salazar J, del Rio E, Baiget M, Altés A, Marcuello E, et al. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(20):3468; author reply 3468-9.